SAN ANTONIO (EGMN) - Women with estrogen receptor–positive early breast cancer have better disease-free survival and relapse-free survival, and longer time to distant metastasis with adjuvant exemestane than with tamoxifen, based on the results of the first planned analysis of the tamoxifen exemestane adjuvant multinational (TEAM) phase III trial. Disease-free survival (DFS) at 2.75 years of follow-up favored exemestane over tamoxifen, with a hazard ratio of 0.89 (P = .12). Relapse-free survival...